<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>肺癌前沿 | wechat-feeds</title><link>http://MzAwMzIwODEwNQ.favicon.privacyhide.com/favicon.ico</link><description>传递最新肺癌信息</description><managingEditor> (hellodword)</managingEditor><pubDate>Fri, 11 Jun 2021 11:26:03 +0800</pubDate><image><url>http://MzAwMzIwODEwNQ.favicon.privacyhide.com/favicon.ico</url><title>肺癌前沿 | wechat-feeds</title><link>http://MzAwMzIwODEwNQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>【2021AACR+ASCO】Checkmate-816新辅助免疫联合化疗研究</title><link>https://mp.weixin.qq.com/s/IRQ1hm5_D3FVABPL1yyOuw</link><description></description><content:encoded><![CDATA[【2021AACR+ASCO】Checkmate-816新辅助免疫联合化疗研究]]></content:encoded><pubDate>Fri, 11 Jun 2021 10:53:45 +0800</pubDate></item><item><title>Trick or treats : 肿瘤君的一千个耐药的理由，Cancer Disvovery Episode</title><link>https://mp.weixin.qq.com/s/M6EbjW4kHXbRV4hAwi221w</link><description></description><content:encoded><![CDATA[Trick or treats : 肿瘤君的一千个耐药的理由，Cancer Disvovery Episode]]></content:encoded><pubDate>Tue, 08 Jun 2021 15:53:45 +0800</pubDate></item><item><title>2021ASCO-PACIFIC研究5年OS数据更新：43%患者存活超5年，33%患者5年无复发</title><link>https://mp.weixin.qq.com/s/Wxru1JvUItDcgqbSvoypjA</link><description></description><content:encoded><![CDATA[2021ASCO-PACIFIC研究5年OS数据更新：43%患者存活超5年，33%患者5年无复发]]></content:encoded><pubDate>Sun, 06 Jun 2021 18:59:04 +0800</pubDate></item><item><title>肺癌患者可以接种新冠疫苗吗？</title><link>https://mp.weixin.qq.com/s/9hG06P9iZX9Ot3oHa6gNqQ</link><description></description><content:encoded><![CDATA[肺癌患者可以接种新冠疫苗吗？]]></content:encoded><pubDate>Wed, 26 May 2021 00:31:54 +0800</pubDate></item><item><title>时光掠影：I-III期非小细胞肺癌治疗策略演化之路</title><link>https://mp.weixin.qq.com/s/_9Mei0q1v_QfFOI1xfQ7ng</link><description></description><content:encoded><![CDATA[时光掠影：I-III期非小细胞肺癌治疗策略演化之路]]></content:encoded><pubDate>Thu, 20 May 2021 11:24:51 +0800</pubDate></item><item><title>JCOG0802非劣RCT：肺结节(小于2cm，实性为主)肺段切除，Less is More？</title><link>https://mp.weixin.qq.com/s/WE563H12NEASj4llGH4FbQ</link><description></description><content:encoded><![CDATA[JCOG0802非劣RCT：肺结节(小于2cm，实性为主)肺段切除，Less is More？]]></content:encoded><pubDate>Wed, 05 May 2021 15:58:03 +0800</pubDate></item><item><title>[Cancer Discovery]靶向肿瘤微环境的治疗策略</title><link>https://mp.weixin.qq.com/s/v08ycwOW1Q37l4KaYStKcQ</link><description></description><content:encoded><![CDATA[[Cancer Discovery]靶向肿瘤微环境的治疗策略]]></content:encoded><pubDate>Thu, 29 Apr 2021 16:54:33 +0800</pubDate></item><item><title>劳拉替尼是否应该成为ALK 融合NSCLC 新的一线标准方案? Pros and Cons</title><link>https://mp.weixin.qq.com/s/S7wfIbpTnPKTd865vm1czg</link><description></description><content:encoded><![CDATA[劳拉替尼是否应该成为ALK 融合NSCLC 新的一线标准方案? Pros and Cons]]></content:encoded><pubDate>Mon, 26 Apr 2021 21:29:04 +0800</pubDate></item><item><title>Osimertinib之外 3代EGFR-TKI 开发现状综述</title><link>https://mp.weixin.qq.com/s/TApfrzORYqqOQEugT6bCjg</link><description></description><content:encoded><![CDATA[Osimertinib之外 3代EGFR-TKI 开发现状综述]]></content:encoded><pubDate>Sat, 24 Apr 2021 18:03:43 +0800</pubDate></item><item><title>Trick or treats : 肿瘤君的一千个耐药的理由，CD Episode and Nat Ca</title><link>https://mp.weixin.qq.com/s/mBT6HW-lCMC56KWY7L1k1g</link><description></description><content:encoded><![CDATA[Trick or treats : 肿瘤君的一千个耐药的理由，CD Episode and Nat Ca]]></content:encoded><pubDate>Sun, 18 Apr 2021 15:48:52 +0800</pubDate></item></channel></rss>